In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of Plus Therapeutics Inc (NASDAQ: PSTV) was $0.68 for the day, up 0.69% from the previous closing price of $0.68. In other words, the price has increased by $0.69 from its previous closing price. On the day, 16.62 million shares were traded. PSTV stock price reached its highest trading level at $0.694 during the session, while it also had its lowest trading level at $0.6425.
Ratios:
Our analysis of PSTV’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.20 and its Current Ratio is at 1.20. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On March 17, 2025, D. Boral Capital started tracking the stock assigning a Buy rating and target price of $9.
On January 25, 2021, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $8.Ladenburg Thalmann initiated its Buy rating on January 25, 2021, with a $8 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 22 ’25 when Lenk Robert P bought 110,000 shares for $0.49 per share. The transaction valued at 53,779 led to the insider holds 139,327 shares of the business. Petersen Greg bought 36,666 shares of PSTV for $20,276 on May 15 ’25.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PSTV now has a Market Capitalization of 67748040 and an Enterprise Value of 60899040. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.73 while its Price-to-Book (P/B) ratio in mrq is 20.74. Its current Enterprise Value per Revenue stands at 11.454 whereas that against EBITDA is -5.011.
Stock Price History:
The Beta on a monthly basis for PSTV is 0.78, which has changed by -0.47692305 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, PSTV has reached a high of $2.31, while it has fallen to a 52-week low of $0.16. The 50-Day Moving Average of the stock is 25.67%, while the 200-Day Moving Average is calculated to be -6.26%.
Shares Statistics:
PSTV traded an average of 22.30M shares per day over the past three months and 71634160 shares per day over the past ten days. A total of 99.26M shares are outstanding, with a floating share count of 99.00M. Insiders hold about 0.26% of the company’s shares, while institutions hold 3.19% stake in the company. Shares short for PSTV as of 1757894400 were 4066506 with a Short Ratio of 0.18, compared to 1755216000 on 3124941. Therefore, it implies a Short% of Shares Outstanding of 4066506 and a Short% of Float of 4.099999700000001.
Earnings Estimates
. The current rating of Plus Therapeutics Inc (PSTV) is the result of assessments by 1.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.03, with high estimates of -$0.03 and low estimates of -$0.03.
Analysts are recommending an EPS of between -$0.33 and -$0.33 for the fiscal current year, implying an average EPS of -$0.33. EPS for the following year is -$0.38, with 2.0 analysts recommending between -$0.14 and -$0.61.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 4 analysts. It ranges from a high estimate of $3.32M to a low estimate of $189k. As of. The current estimate, Plus Therapeutics Inc’s year-ago sales were $1.46MFor the next quarter, 4 analysts are estimating revenue of $1.62M. There is a high estimate of $3.63M for the next quarter, whereas the lowest estimate is $700k.
A total of 3 analysts have provided revenue estimates for PSTV’s current fiscal year. The highest revenue estimate was $9.4M, while the lowest revenue estimate was $947k, resulting in an average revenue estimate of $5.19M. In the same quarter a year ago, actual revenue was $5.82MBased on 4 analysts’ estimates, the company’s revenue will be $6.34M in the next fiscal year. The high estimate is $12.11M and the low estimate is $4M.
